Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TACR1 | P25103 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220264 | 1.00 | MAPT (0.67) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL29534060 | 0.99 | KDM4E (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL6745399 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL475351 | 0.92 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL289044 | 0.92 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL3873457 | 0.90 | MAPT (0.64) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL21059260 | 0.89 | MAPT (0.70) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL120931 | 0.88 | KDM4E (0.69) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL5065255 | 0.88 | KDM4E (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL17503190 | 0.88 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748385-A1 | BLOOD PLASMA FRACTIONS AS A TREATMENT FOR AGING-ASSOCIATED COGNITIVE DISORDERS | Alkahest, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4719440-A1 | COMPOSITIONS OF BLOOD PLASMA FRACTIONS AND BLOOD PLASMA SUBFRACTIONS AND THEIR USE IN TREATMENT OF DISEASE | Alkahest, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4054597-B1 | BLOOD PLASMA FRACTIONS FOR USE IN MUSCLE REGENERATION | ALKAHEST INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4689665-A1 | COMPOSITIONS AND METHODS OF PREPARATION OF BLOOD PLASMA PRODUCTS WITH REDUCED LEVELS OF FCERISS AUTOANTIBODIES | Grifols Worldwide Operations Limited (IE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024258622-A9 | BLOOD PLASMA FRACTIONS AS A TREATMENT FOR CHEMOTHERAPY INDUCED COGNITIVE DISORDERS | ALKAHEST, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615488-A1 | BLOOD PLASMA FRACTIONS FOR IMPROVEMENT OF MYELINATION | Alkahest, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025126144-A1 | METHODS OF MONITORING PARAMETERS IN SOLUTION | CSL BEHRING AG (CH) | 2025-06-19 | — | — | WO | disclosed |
| EP-4353320-B1 | BLOOD PLASMA AND PLASMA FRACTIONS AS THERAPY FOR TUMOR GROWTH AND PROGRESSION | ALKAHEST INC (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024258622-A1 | BLOOD PLASMA FRACTIONS AS A TREATMENT FOR CHEMOTHERAPY INDUCED COGNITIVE DISORDERS | ALKAHEST, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240409612-A1 | IMPROVED PURIFICATION PROCESS | CSL BEHRING AG (CH) | 2024-12-12 | — | — | US | disclosed |
| WO-2022245552-A1 | BLOOD PLASMA FRACTIONS FOR USE IN LIVER REGENERATION | ALKAHEST, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11484551-B2 | Method of treating liver failure with plasma fraction IV-4 | ALKAHEST, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-4061384-A1 | BLOOD PLASMA FRACTIONS FOR USE IN LIVER REGENERATION | Alkahest, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-4054597-A1 | BLOOD PLASMA FRACTIONS FOR USE IN MUSCLE REGENERATION | Alkahest, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-11439687-B2 | Blood plasma fractions for use in muscle regeneration | ALKAHEST, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11413308-B2 | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | ALKAHEST, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220152161-A1 | Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders | ALKAHEST, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3995141-A1 | BLOOD PLASMA AND PLASMA FRACTIONS AS THERAPY FOR TUMOR GROWTH AND PROGRESSION | Alkahest, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3995140-A1 | BLOOD PLASMA FRACTIONS AS A TREATMENT FOR AGING-ASSOCIATED COGNITIVE DISORDERS | Alkahest, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11298377-B2 | Methods of improving wound healing | ALKAHEST, INC. (US) | 2022-04-12 | — | — | US | disclosed |